Protective effect of high-dose montelukast on salbutamol-induced homologous desensitisation in airway smooth muscle

Pulmonary Pharmacology and Therapeutics

Volumn 26, Issue 6, 2013, Pages 693-699

  Fogli, Stefano ^a   Stefanelli, Fabio ^a   Martelli, Alma ^a   Daniele, Simona ^a   Testai, Lara ^a   Calderone, Vincenzo ^a   Trincavelli, Maria Letizia ^a   Martini, Claudia ^a   Breschi, Maria Cristina ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Airway smooth muscle; Animal model; Chronic lung diseases; Montelukast; Salbutamol

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; BETA 2 ADRENERGIC RECEPTOR; CARBACHOL; CYCLIC AMP; MONTELUKAST; PHOSPHODIESTERASE; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV D5; SALBUTAMOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRONCHUS MUSCLE; CELL MEMBRANE; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DESENSITIZATION; DRUG DOSE INCREASE; DRUG MEGADOSE; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GUINEA PIG; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LONG TERM EXPOSURE; MALE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SMOOTH MUSCLE RELAXATION; TRACHEA MUSCLE; WESTERN BLOTTING;

AIRWAY SMOOTH MUSCLE; ANIMAL MODEL; BRONCHIAL SMOOTH MUSCLE CELLS; BSMC; CHRONIC LUNG DISEASES; CHRONIC OBSTRUCTIVE PULMONARY DISEASES; COPD; MONTELUKAST; SALBUTAMOL;

ACETATES; ALBUTEROL; ANIMALS; BRONCHI; BRONCHODILATOR AGENTS; CELL MEMBRANE; CYCLIC AMP; CYTOSOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; GENE EXPRESSION PROFILING; GUINEA PIGS; HUMANS; INJECTIONS, INTRAPERITONEAL; LEUKOTRIENE ANTAGONISTS; MALE; MYOCYTES, SMOOTH MUSCLE; QUINOLINES; RECEPTORS, LEUKOTRIENE; TIME FACTORS; TRACHEA;

EID: 84887991994     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2013.06.006     Document Type: Article

References (34)

1. Barnes P.J. Corticosteroids. Asthma and COPD 2009, 639-654. Academic Press, San Diego/Burlington/Amsterdam. P.J. Barnes, J.M. Drazen, S.I. Rennard, N.C. Thompson (Eds.).
2. Kankaanranta H., Lahdensuo A., Moilanen E., Barnes P.J. Add-on therapy options in asthma not adequately controlled by inhaled corticosteroids: a comprehensive review. Respir Res 2004, 5:17.
3. Salpeter S.R. An update on the safety of long-acting beta-agonists in asthma patients using inhaled corticosteroids. Expert Opin Drug Saf 2010, 9:407-419.
4. Taylor D.R. The beta-agonist saga and its clinical relevance: on and on it goes. Am J Respir Crit Care Med 2009, 179:976-978.
5. Nino G., Hu A., Grunstein J.S., Grunstein M.M. Mechanism regulating proasthmatic effects of prolonged homologous beta2-adrenergic receptor desensitisation in airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 2009, 297:L746-L757.
6. Fogli S., Pellegrini S., Adinolfi B., Mariotti V., Melissari E., Betti L., et al. Rosiglitazone reverses salbutamol-induced β(2)-adrenoceptor tolerance in airway smooth muscle. Br J Pharmacol 2011, 162:378-391.
7. Grootendorst D.C., Sterk P.J., Heijerman H.G. Effect of oral prednisolone on the bronchoprotective effect of formoterol in patients with persistent asthma. Eur Respir J 2001, 17:374-379.
8. Hall I.P., Daykin K., Widdop S. Beta 2-adrenoceptor desensitisation in cultured human airway smooth muscle. Clin Sci (Lond) 1993, 84:151-157.
9. Noonan M.J., Chervinsky P., Brandon M., Zhang J., Kundu S., McBurney J., et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur Respir J 1998, 11:1232-1239.
10. Blain J.F., Sirois P. Involvement of LTD(4)in allergic pulmonary inflammation in mice: modulation by cysLT(1)antagonist MK-571. Prostaglandins Leukot Essent Fatty Acids 2000, 62:361-368.
11. Wu A.Y., Chik S.C., Chan A.W., Li Z., Tsang K.W., Li W. Anti-inflammatory effects of high-dose montelukast in an animal model of acute asthma. Clin Exp Allergy 2003, 33:359-366.
12. Al Suleimani Y.M., Dong Y., Walker M.J. Differential responses to various classes of drugs in a model of allergic rhinitis in guinea pigs. Pulm Pharmacol Ther 2008, 21:340-348.
13. Han J., Jia Y., Takeda K., Shiraishi Y., Okamoto M., Dakhama A., et al. Montelukast during primary infection prevents airway hyperresponsiveness and inflammation after reinfection with respiratory syncytial virus. Am J Respir Crit Care Med 2010, 182:455-463.
14. Rovati G.E., Baroffio M., Citro S., Brichetto L., Ravasi S., Milanese M., et al. Cysteinyl-leukotrienes in the regulation of beta2-adrenoceptor function: an invitro model of asthma. Respir Res 2006, 7:103.
15. Eum S.Y., Maghni K., Hamid Q., Campbell H., Eldelman D.H., Martin J.G. Involvement of the cysteinyl-leukotrienes in allergen-induced airway eosinophilia and hyperresponsiveness in the mouse. Am J Respir Cell Mol Biol 2003, 28:25-32.
16. Bahekar P.C., Shah J.H., Ayer U.B., Mandhane S.N., Thennati R. Validation of guinea pig model of allergic rhinitis by oral and topical drugs. Int Immunopharmacol 2008, 8:1540-1551.
17. Cikler E., Ersoy Y., Cetinel S., Ercan F. The leukotriene d4 receptor antagonist, montelukast, inhibits mast cell degranulation in the dermis induced by water avoidance stress. Acta Histochem 2009, 111:112-118.
18. Tsuchida H., Takahashi S., Nosaka E., Kuraya T., Yamashita M., Morimoto K. Novel triple neurokinin receptor antagonist CS-003 inhibits respiratory disease models in guinea pigs. Eur J Pharmacol 2008, 596:153-159.
19. Muz M.H., Deveci F., Bulut Y., Ilhan N., Yekeler H., Turgut T. The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model. Exp Mol Med 2006, 38:109-118.
20. Guay D., Gauthier J.Y., Dufresne C., Jones T.R., McAuliffe M., McFarlane C., et al. Aseries of non-quinoline cysLT1 receptor antagonists: SAR study on pyridyl analogs of Singulair. Bioorg Med Chem Lett 1998, 8:453-458.
21. Mak J.C., Nishikawa M., Shirasaki H., Miyayasu K., Barnes P.J. Protective effects of a glucocorticoid on downregulation of pulmonary beta 2-adrenergic receptors invivo. JClin Invest 1995, 96:99-106.
22. Nishikawa M., Mak J.C., Shirasaki H., Barnes P.J. Differential down-regulation of pulmonary beta 1- and beta 2-adrenoceptor messenger RNA with prolonged invivo infusion of isoprenaline. Eur J Pharmacol 1993, 247:131-138.
23. Nishikawa M., Mak J.C., Shirasaki H., Harding S.E., Barnes P.J. Long-term exposure to norepinephrine results in down-regulation and reduced mRNA expression of pulmonary beta-adrenergic receptors in guinea pigs. Am J Respir Cell Mol Biol 1994, 10:91-99.
24. Hu A., Nino G., Grunstein J.S., Fatma S., Grunstein M.M. Prolonged heterologous beta2-adrenoceptor desensitisation promotes proasthmatic airway smooth muscle function via PKA/ERK1/2-mediated phosphodiesterase-4 induction. Am J Physiol Lung Cell Mol Physiol 2008, 294:L1055-L1067.
25. Bruss M.D., Richter W., Horner K., Jin S.L., Conti M. Critical role of PDE4D in beta2-adrenoceptor-dependent cAMP signaling in mouse embryonic fibroblasts. JBiol Chem 2008, 283:22430-22442.
26. Xin W., Tran T.M., Richter W., Clark R.B., Rich T.C. Roles of GRK and PDE4 activities in the regulation of beta2 adrenergic signaling. JGen Physiol 2008, 131:349-364.
27. Billington C.K., Le Jeune I.R., Young K.W., Hall I.P. Amajor functional role for phosphodiesterase 4D5 in human airway smooth muscle cells. Am J Respir Cell Mol Biol 2008, 38:1-7.
28. Le Jeune I.R., Shepherd M., Van Heeke G., Houslay M.D., Hall I.P. Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter. JBiol Chem 2002, 277:35980-35989.
29. Trian T., Burgess J.K., Niimi K., Moir L.M., Ge Q., Berger P., et al. β2-Agonist induced cAMP is decreased in asthmatic airway smooth muscle due to increased PDE4D. PLoS One 2011, 6:e20000.
30. Tintinger G.R., Feldman C., Theron A.J., Anderson R. Montelukast: more than a cysteinyl leukotriene receptor antagonist?. ScientificWorldJournal 2010, 10:2403-2413.
31. Kojo H., Fukagawa M., Tajima K., Suzuki A., Fujimura T., Aramori I., et al. Evaluation of human peroxisome proliferator-activated receptor (PPAR) subtype selectivity of a variety of anti-inflammatory drugs based on a novel assay for PPAR delta(beta). JPharmacol Sci 2003, 93:347-355.
32. Janneh O., Hartkoorn R.C., Jones E., Owen A., Ward S.A., Davey R., et al. Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. Br J Pharmacol 2008, 155:875-883.
33. Schoors D.F., De Smet M., Reiss T., Margolskee D., Cheng H., Larson P., et al. Single dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D4-receptor antagonist, in healthy volunteers. Br J Clin Pharmacol 1995, 40:277-280.
34. Storms W., Michele T.M., Knorr B., Noonan G., Shapiro G., Zhang J., et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or= 6 years. Clin Exp Allergy 2001, 31:77-87.